13 results on '"Amorim Filho L"'
Search Results
2. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) by A Third Dose of Chadox1 Ncov-19 (Astrazeneca) After BNT162b2 (Pfizer–BioNTech)
- Author
-
Costa-Filho RC, Penna Luz C, Monteiro de Souza ATA, Tantos Nunes G, Melo Amorim Filho L, Saddy F, and de Castro Faria-Neto HC
- Abstract
An atypical case of VITT was described resulting from a vaccination schedule where the third booster with ChAdOx1 nCoV-19 (AstraZeneca) was administered. The patient received a complete vaccination schedule with two doses of Pfizer–BioNTech (BNT162b2) without any complications before the third dose. However, the patient has developed an infrequent yet extreme prothrombotic; hypercoagulable state caused by platelet-activating anti-platelet factor 4 (PF4) antibodies. This phenomenon is typically triggered by the proximate administration of an adenoviral vector vaccine against COVID-19. The patient’s symptoms began ten days after taking the third dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca). His main complaints when hospitalized were severe headaches and right abdominal pain. The blood tests and MRI scan imaging findings were very characteristic of VITT, and a rare cerebral venous sinus thrombosis was found. Also, a markedly elevated D-dimer and strong positive PF4-dependent enzyme- immunoassay test results were documented. Due to discerning clinical suspicion, this patient was rapidly treated with immunoglobulin infusion for two days and oral steroids for three days. Subsequently, he was anticoagulated with the new oral anticoagulant edoxaban after platelet numbers recovery. In a few days, platelets normalized, and D-dimer levels decreased, while anti- PF4-dependent enzyme-immunoassay test results showed a slow decline. He was discharged taking oral edoxaban without any squeal.
- Published
- 2022
3. FALTA DE EVIDÊNCIA DA INFECÇÃO POR ENTEROVÍRUS NOS DOADORES DE SANGUE NO RIO DE JANEIRO, BRASIL, 2022
- Author
-
Nunes, GT, primary, Oliveira, AS, additional, Lopes, JIF, additional, Silva, JA, additional, Silva, CACE, additional, Amorim-Filho, L, additional, Paula, VS, additional, and Sousa-Júnior, IP, additional
- Published
- 2022
- Full Text
- View/download PDF
4. VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT) BY A THIRD DOSE OF CHADOX1 NCOV-19 (ASTRAZENECA) AFTER BNT162B2 (PFIZER–BIONTECH)
- Author
-
Costa-Filho, R, primary, Luz, CP, additional, Souza, ATAM, additional, Nunes, GT, additional, Amorim-Filho, L, additional, Saddy, F, additional, and Faria-Neto, HCC, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Detection of Plasmodium spp. in asymptomatic blood donors by the new Brazilian NAT PLUS HIV/HBV/HCV/Malaria Bio-Manguinhos kit.
- Author
-
Costa E, Rocha D, Lopes JIF, Andrade E, Cardoso P, Ribeiro M, Fontana-Maurell M, Vicentino ARR, Calazans AR, Arruda MB, Mesquita CA, Ferreira AGP, Amorim Filho L, and Alvarez P
- Subjects
- Humans, Hepatitis B virus, Blood Donors, Brazil epidemiology, Plasmodium malariae, Malaria diagnosis, Malaria epidemiology, HIV Infections diagnosis, HIV Infections epidemiology, Hepatitis C
- Abstract
Background: Transfusion-transmitted malaria (TTM) is a public health problem in endemic and nonendemic areas. The Brazilian Ministry of Health (MH) requested the development of a nucleic acid amplification test (NAT) for the detection of Plasmodium spp. in public blood centers to increase blood safety., Study Design and Methods: The new Brazilian NAT kit named NAT PLUS HIV/HBV/HCV/Malaria Bio-Manguinhos was first implemented in HEMORIO, a public blood center in the city of Rio de Janeiro. Since October 1, 2022, this blood center has been testing all its blood donations for malaria in a pool of six plasma samples to detect Plasmodium spp. by real-time polymerase chain reaction (PCR)., Results: Since the implementation of the NAT PLUS platform until February 2023, HEMORIO has successfully received and tested 200,277 donations. The platform detected two asymptomatic donors in the city of Rio de Janeiro, which is a nonendemic region for malaria. Our analyses suggested a malaria from the Amazon region caused by Plasmodium vivax, in the first case, while an autochthonous transmission case by Plasmodium malariae was identified in the rural area of Rio de Janeiro state., Discussion: The NAT PLUS platform detects Plasmodium spp. in plasma samples with sensitivity capable of detecting subpatent infections. This is the first time worldwide that a group developed and implemented molecular diagnosis for Plasmodium spp. to be used by public blood centers to avoid TTM., (© 2024 AABB.)
- Published
- 2024
- Full Text
- View/download PDF
6. Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series.
- Author
-
Mendes-de-Almeida DP, Mouta Nunes de Oliveira P, Bertollo Gomes Porto V, Saraiva Pedro R, Takey PRG, Lignani LK, Vitiello Teixeira G, Pereira TDS, Abreu DL, Xavier JR, Castro TDM, Melo de Amorim Filho L, and Sousa Maia ML
- Abstract
Background: The emergence of new variants of SARS-CoV-2 has led to the administration of different booster vaccines to mitigate COVID-19. Vaccines with adenoviral vectors have been rarely associated with vaccine-induced immune thrombotic thrombocytopenia (VITT)., Objectives: This study aimed to describe 15 cases of VITT after the third and fourth doses of the COVID-19 vaccine in Brazil., Methods: Cases were reported after all kinds of anti-SARS-CoV-2 booster vaccinations between October 17, 2021, and September 4, 2022., Results: Of the 26 suspected cases, 15 cases of VITT were analyzed. Of these, 10 were classified as definite VITT, 2 as probable, 1 as possible, and 2 as unlikely. The estimated frequency of definite, probable, or possible VITT was 0.33 cases per million. Cases were assigned to ChAdOx1 (13 cases), Ad26.COV2.S (1 case), and BNT162b2 (1 case). None of the patients received an adenoviral vaccine as a primary vaccination. The average age of participants was 34 years, and symptoms usually appeared 8 days after vaccination. Headache was the most common symptom, and cerebral veins were the most affected thrombotic site. The overall mortality risk was 53%. Anti-platelet factor 4 enzyme-linked immunosorbent assay serology was positive in 11 out of 15 patients (73.3%), negative in 2 (13.3%), and missing in 2 (13.3%)., Conclusion: The study confirms that VITT is linked to the first exposure to adenoviral vector vaccines. Since January 2023, Brazil has recommended preferably COVID-19 messenger RNA vaccines for individuals aged 18 to 39 years. We suggest that, in the current disease scenario, COVID-19 adenovirus vaccines should not be the first choice for individuals aged <50 years who have not received a previous dose of this type of vaccine., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
7. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
- Author
-
Mouta Nunes de Oliveira P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, Vitiello Teixeira G, Saraiva Pedro R, Roberto Gomes Takey P, Kegele Lignani L, Reis Xavier J, Cardoso Doria da Gama V, Amorim Filho L, Emoingt Furtado B, Santa Maria A, Dahrug Barros T, Neves Waite Freitas L, Dos Santos Pereira T, Lima Abreu D, Bernardes Ramos M, Gabe C, Arnold D, William Smith J, Nazy I, and Lourdes de Sousa Maia M
- Subjects
- Ad26COVS1, Adult, BNT162 Vaccine, Brazil epidemiology, ChAdOx1 nCoV-19, Female, Humans, Vaccination adverse effects, Vaccines adverse effects, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Thrombocytopenia chemically induced, Thrombocytopenia epidemiology, Thrombosis chemically induced, Thrombosis epidemiology
- Abstract
Objective: Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory characteristics., Methodology: Descriptive case series study using Bio-Manguinhos/Fiocruz/AstraZeneca Brazil and National Immunization Program/Ministry of Health (NIP/MoH) data on COVID-19 AEFI surveillance. We obtained patient-level data from pharmacovigilance for AEFI surveillance and used both the NIP/MoH and Bio-Manguinhos/Fiocruz pharmacovigilance databases to create the study database. Thirty-nine cases of suspect VITT were included, 36 after ChAdOx1 nCoV-19, one after BNT162b2 and two after Ad26.COV2.S vaccine. All cases were based on meeting the Brighton Collaboration criteria for VITT. The primary outcomes were clinical and laboratory features, site of thrombosis, and anti-PF4 ELISA, when available., Results: Thirty-nine cases met the criteria, 38 of which were classified as level 1 and one as level 3 according to Brighton Collaboration. Most cases had the central nervous system (CNS) as the main site of thrombosis (21/39) and happened after the vaccine first dose (34/39). The median age of the cases was 41 years old (23 to 86 yo). Most of the cases (61.5%) occurred in women. The median interval between vaccination and onset of symptoms was 8 days (0-37 days). The platelet count and D-dimer count had median values of 34,000/µL and 19,235 µg FEU/L, respectively. The ELISA anti-PF4 antibody was positive in 18 samples. The overall mortality rate was 51% and was higher in cases of CNS thrombosis with intracerebral bleeding., Conclusion: Our case series shows that Brazilian VITT cases have similar clinical and laboratory profiles as demonstrated in the literature. Brazil has administered more than 300 million doses of COVID-19 vaccines (more than 110 million from ChAdOx1 nCoV-19). VITT seems to be a very rare but serious adverse event following COVID-19 immunization, especially adenoviral vector immunization., Competing Interests: Declaration of Competing Interest Patricia Mouta Nunes de Oliveira ,Catherine Crespo Cordeiro, Debora Lima Abreu, Gabriellen Vitiello Teixeira, Janaina Reis Xavier, Letícia Kegele Lignani, Livia Neves Waite Freitas, Maria de Lourdes de Sousa Maia, Michael Bernardes Ramos, Patricia Mouta Nunes de Oliveira, Paulo Roberto Gomes Takey, Renata Saraiva Pedro, Tainá dos Santos Pereira, and Vitor Cardoso da Gama are employees of the Immunobiological Technology Institute/Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), Marketing Authorization Holder of the covid-19 vaccine (recombinant)* in Brazil. Bárbara Emoingt Furtado and André Santa Maria reports a relationship with AstraZeneca Brasil that includes: employment. employee of AstraZeneca Brasil , Marketing Authorization Holder of the covid-19 vaccine (recombinant)* in Brazil. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
8. A Large Cohort Study of SARS-CoV-2 Detection in Saliva: A Non-Invasive Alternative Diagnostic Test for Patients with Bleeding Disorders.
- Author
-
Lopes JIF, da Costa Silva CA, Cunha RG, Soares AM, Lopes MED, da Conceição Neto OC, Alves ADR, da Costa Nunes Pimentel Coelho WL, Amorim Filho L, and Amado Leon LA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, COVID-19 virology, COVID-19 Testing, Child, Child, Preschool, Cohort Studies, Diagnostic Tests, Routine, Female, Health Personnel, Humans, Infant, Male, Middle Aged, Saliva, Viral Load, Young Adult, Blood Coagulation Disorders complications, COVID-19 complications, COVID-19 diagnosis, Hemorrhagic Disorders complications, SARS-CoV-2 isolation & purification
- Abstract
Diagnosis of SARS-CoV-2 infections is mostly based on the nasopharyngeal swabs (NPS). However, this collection is invasive and uncomfortable, especially for children and patients with coagulopathies, whose NPS collection often causes bleeding. Thus, the aim of this study was to evaluate the usefulness and accuracy of saliva for the diagnosis of COVID-19 in patients presenting bleeding disorders. Samples of NPS, oropharyngeal swabs (OPS), and saliva were collected simultaneously from 1159 hospitalized patients with hematological diseases and from 524 healthcare workers, both symptomatic and asymptomatic for SARS-CoV-2. All samples were evaluated for SARS-CoV-2 by qRT-PCR. SARS-CoV-2 was detected in NPS, OPS and saliva from 16.9%, 14.4% and 15.6% individuals, respectively. Tests in saliva showed sensitivity, specificity, and overall agreement of 73.3%, 96.9% and 92.7% (=0.74), respectively. Salivary tests had good accuracy (AUC = 0.7) for discriminating negative and positive qRT-PCR for SARS-CoV-2. Higher sensitivity was observed in symptomatic than in non-symptomatic patients, as well as in healthy subjects than in patients with hematological disease, in both OPS and saliva. The mean viral load in NPS was significantly higher than in OPS and in saliva samples ( p < 0.001). Saliva is a good diagnostic tool to detect SARS-CoV-2, especially among patients symptomatic for COVID-19, and is a valuable specimen for mass screening of hospitalized patients with hematological diseases, especially for those that with bleeding disorders.
- Published
- 2021
- Full Text
- View/download PDF
9. 10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil.
- Author
-
de Oliveira Garcia Mateos S, Preiss L, Gonçalez TT, Di Lorenzo Oliveira C, Grebe E, Di Germanio C, Stone M, Amorim Filho L, Carneiro Proietti AB, Belisario AR, de Almeida-Neto C, Mendrone-Junior A, Loureiro P, Busch MP, Custer B, and Cerdeira Sabino E
- Subjects
- Adult, Brazil epidemiology, Female, Humans, Incidence, Male, Middle Aged, Young Adult, Blood Safety, HIV Infections epidemiology, Transfusion Reaction epidemiology
- Abstract
Background and Objectives: Incidence in first-time and repeat blood donors is an important measure of transfusion-transmitted HIV infection (TT-HIV) risk. This study assessed HIV incidence over time at four large blood centres in Brazil., Materials and Methods: Donations were screened and confirmed using serological assays for HIV from 2007 to 2016, and additionally screened by nucleic acid testing from 2011 forward. Limiting antigen (LAg) avidity testing was conducted on HIV seroreactive samples from first-time donors to classify whether an infection was recently acquired. We calculated incidence in first-time donors using the mean duration of recent infection and in repeat donors using classical methods. Time and demographic trends were assessed using Poisson regression., Results: Over the 10-year period, HIV incidence in first-time donors was highest in Recife (45·1/100 000 person-years (10
5 py)) followed by São Paulo (32·2/105 py) and then Belo Horizonte (23·3/105 py), and in repeat donors was highest in Recife (33·2/105 py), Belo Horizonte (27·5/105 py) and São Paulo (17·0/105 py). Results from Rio de Janeiro were available from 2013 to 2016 with incidence in first-time donors of 35·9/105 py and repeat donors from 2011 to 2016 of 29·2/105 py. Incidence varied by other donor demographics. When incidence was considered in 2-year intervals, no significant trend was evident. Overall residual risk of TT-HIV was 5·46 and 7·41 per million units of pRBC and FFP transfused, respectively., Conclusion: HIV incidence in both first-time and repeat donors varied by region in Brazil. Clear secular trends were not evident., (© 2020 International Society of Blood Transfusion.)- Published
- 2021
- Full Text
- View/download PDF
10. Vox Sanguinis International Forum on Hospital Transfusion Services' Response to COVID-19: Responses.
- Author
-
Yazer MH, Jackson B, Pagano M, Rahimi-Levene N, Peer V, Bueno JL, Jackson RP, Shan H, Amorim-Filho L, Lopes ME, Boquimpani C, Sprogøe U, Bruun MT, Titlestad K, Rushford K, Wood EM, McQuilten ZK, de Angelis V, Donne MD, Murphy M, Staves J, Cho D, Nakamura F, Hangaishi A, Callum J, Lin Y, Mogaddam M, Gharehbaghian A, and Lozano M
- Subjects
- Blood Banks statistics & numerical data, Blood Transfusion statistics & numerical data, COVID-19, Coronavirus Infections transmission, Disease Transmission, Infectious prevention & control, Health Personnel standards, Humans, Pandemics, Pneumonia, Viral transmission, Practice Guidelines as Topic, Blood Banks standards, Blood Transfusion standards, Coronavirus Infections epidemiology, Health Knowledge, Attitudes, Practice, Health Personnel psychology, Pneumonia, Viral epidemiology, Surveys and Questionnaires
- Published
- 2020
- Full Text
- View/download PDF
11. Vox Sanguinis International Forum on transfusion services' response to COVID-19: Summary.
- Author
-
Yazer MH, Jackson B, Pagano M, Rahimi-Levene N, Peer V, Bueno JL, Jackson RP, Shan H, Amorim-Filho L, Lopes ME, Boquimpani C, Sprogøe U, Topholm Bruun M, Titlestad K, Rushford K, Wood EM, McQuilten ZK, de Angelis V, Delle Donne M, Murphy M, Staves J, Cho D, Nakamura F, Hangaishi A, Callum J, Lin Y, Mogaddam M, Gharehbaghian A, and Lozano M
- Subjects
- Blood Banks statistics & numerical data, Blood Donors statistics & numerical data, Blood Safety statistics & numerical data, Blood Transfusion statistics & numerical data, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques standards, Clinical Laboratory Techniques statistics & numerical data, Coronavirus Infections diagnosis, Coronavirus Infections transmission, Disease Transmission, Infectious prevention & control, Health Knowledge, Attitudes, Practice, Health Personnel psychology, Humans, Pandemics, Pneumonia, Viral transmission, Blood Banks standards, Blood Safety standards, Blood Transfusion standards, Coronavirus Infections epidemiology, Health Personnel standards, Pneumonia, Viral epidemiology, Surveys and Questionnaires
- Published
- 2020
- Full Text
- View/download PDF
12. Optimisation and control of the supply of blood bags in hemotherapic centres via Markov decision process with discounted arrival rate.
- Author
-
Soares HLF, Arruda EF, Bahiense L, Gartner D, and Amorim Filho L
- Subjects
- Humans, Probability, Markov Chains
- Abstract
Running a cost-effective human blood transfusion supply chain challenges decision makers in blood services world-wide. In this paper, we develop a Markov decision process with the objective of minimising the overall costs of internal and external collections, storing, producing and disposing of blood bags, whilst explicitly considering the probability that a donated blog bag will perish before demanded. The model finds an optimal policy to collect additional bags based on the number of bags in stock rather than using information about the age of the oldest item. Using data from the literature, we validate our model and carry out a case study based on data from a large blood supplier in South America. The study helped achieve an overall increase of 4.5% in blood donations in one year., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil.
- Author
-
Amorim Filho L, Szwarcwald CL, Mateos SOG, Leon ACMP, Medronho RA, Veloso VG, Lopes JIF, Porto LCMS, Chieppe A, and Werneck GL
- Subjects
- Adult, Aged, Brazil epidemiology, COVID-19, Coronavirus Infections blood, Coronavirus Infections epidemiology, Cross-Sectional Studies, Female, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Male, Middle Aged, Pandemics, Pneumonia, Viral blood, Pneumonia, Viral epidemiology, Prevalence, Regression Analysis, SARS-CoV-2, Sensitivity and Specificity, Seroepidemiologic Studies, Young Adult, Antibodies, Viral blood, Betacoronavirus immunology, Blood Donors statistics & numerical data, Coronavirus Infections immunology, Pneumonia, Viral immunology
- Abstract
OBJECTIVE To estimate the seroprevalence of antibodies to SARS-CoV-2 among blood donors in the state of Rio de Janeiro, Brazil. METHODS Data were collected on 2,857 blood donors from April 14 to 27, 2020. This study reports crude prevalence of antibodies to SARS-CoV-2, population weighted prevalence for the state, and prevalence adjusted for test sensitivity and specificity. Logistic regression models were used to establish the correlates of SARS-CoV-2 prevalence. For the analysis, we considered collection period and site, sociodemographic characteristics, and place of residence. RESULTS The proportion of positive tests for SARS-Cov-2, without any adjustment, was 4.0% (95%CI 3.3-4.7%), and the weighted prevalence was 3.8% (95%CI 3.1-4.5%). We found lower estimates after adjusting for test sensitivity and specificity: 3.6% (95%CI 2.7-4.4%) for the non-weighted prevalence, and 3.3% (95%CI 2.6-4.1%) for the weighted prevalence. Collection period was the variable most significantly associated with crude prevalence: the later the period, the higher the prevalence. Regarding sociodemographic characteristics, the younger the blood donor, the higher the prevalence, and the lower the education level, the higher the odds of testing positive for SARS-Cov-2 antibody. We found similar results for weighted prevalence. CONCLUSIONS Our findings comply with some basic premises: the increasing trend over time, as the epidemic curve in the state is still on the rise; and the higher prevalence among both the youngest, for moving around more than older age groups, and the less educated, for encountering more difficulties in following social distancing recommendations. Despite the study limitations, we may infer that Rio de Janeiro is far from reaching the required levels of herd immunity against SARS-CoV-2.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.